Why does injectable Testosterone Cypionate have higher bioavailability than oral testosterone?

Injectable Testosterone Cypionate bypasses first-pass hepatic metabolism entirely, delivering close to 100% of the injected dose into systemic circulation. Oral testosterone, by contrast, is degraded extensively in the gastrointestinal tract and liver before reaching the bloodstream, with published pharmacokinetic data indicating only 2–12% of the oral dose survives to produce systemic androgenic effect.

What exactly is first-pass metabolism and how does it affect testosterone compounds?

First-pass metabolism refers to the liver's pre-systemic elimination of a compound absorbed from the gut before it reaches general circulation. For testosterone, this process is so extensive that unmodified oral testosterone is pharmacologically ineffective at standard doses. It is why oral androgens require structural modification (17-alpha alkylation) to survive liver transit — modifications that simultaneously introduce hepatotoxicity risk absent from injectable ester formulations like Testo-C 300.

How quickly does Testosterone Cypionate absorb after an intramuscular injection?

After intramuscular injection of an oil-based cypionate preparation, the depot begins releasing free testosterone as tissue esterases cleave the cypionate ester bond. Measurable serum testosterone elevation occurs within 24–48 hours, with peak plasma concentrations typically reached between 48 and 96 hours post-injection. This gradual, sustained absorption profile distinguishes long-ester injectables from both oral forms and short-ester injectable preparations.

Can I draw GenTec Testo-C 300 into an insulin syringe, and what needle gauge is recommended?

Due to its oil-based carrier and 300 mg/ml concentration, Testo-C 300 is viscous and not well-suited for drawing through insulin syringe gauges. The recommended practice is to draw the dose using an 18–21 gauge needle to overcome oil resistance, then swap to a finer 23–25 gauge needle for the actual intramuscular injection to minimise injection-site discomfort and tissue trauma.

How should a GenTec Testo-C 300 vial be stored after first opening?

After the rubber septum is first punctured, the vial should be stored upright at room temperature (15–25°C), away from direct light and heat sources. Refrigeration is not required but is acceptable; however, cold oil increases viscosity and should be warmed to room temperature before drawing. The benzyl alcohol preservative system in multi-dose vials maintains sterility for the duration of use when aseptic technique is observed consistently between punctures. (2) angle_used

New Formula

GenTec

Testo-C 300 300mg/ml 10ml Vial by GenTec

Name: Testo-C 300 300mg/ml 10ml Vial by GenTec
Brand: GenTec
SKU: INJ-TCYP-GEN-300-009
Price: 36.00 EUR
Availability: InStock

GenTec Testo-C 300 is a multi-dose injectable oil solution delivering Testosterone Cypionate at 300 mg per millilitre — engineered around the principle that intramuscular depot administration bypasses hepatic first-pass metabolism entirely, yielding near-complete systemic bioavailability compared to oral testosterone formulations that typically retain only 2–12% of the administered dose after liver processing. Each 10 ml vial supplies a full anabolic cycle dose at a high-concentration 300 mg/ml specification, maximising the amount of active testosterone reaching circulation per injection. Batch-release integrity is maintained through reversed-phase HPLC potency verification and LAL endotoxin screening; every vial cleared under GMP-compliant manufacturing conditions before distribution.

€36.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Near-complete systemic delivery — intramuscular depot administration eliminates hepatic first-pass losses that discard up to 98% of oral testosterone doses
High-concentration 300 mg/ml formula reduces per-dose injection volume compared to standard 200 mg/ml preparations
Sustained androgenic elevation maintained over multiple days from a single injection due to cypionate ester depot kinetics
No liver-burden hepatotoxicity associated with this injectable ester form, unlike 17-alpha alkylated oral androgens
10 ml multi-dose vial format with preserved septum supports an extended administration schedule from one container
HPLC-verified potency ensures the stated 300 mg/ml concentration is pharmacologically accurate at batch release
LAL endotoxin-tested solution confirms pyrogen-free status, critical for injectable preparations administered directly into muscle tissue

Phase	Dosage	Note
Bioavailability Establishment (Weeks 1–2)	300 mg (1 ml) twice in week 1, then 300 mg weekly	Front-loading accelerates depot saturation, reaching steady-state serum levels faster given the cypionate ester's release kinetics
Maintenance / Anabolic Phase (Weeks 3–12)	300–600 mg per week (1–2 ml), split across two injections	Splitting weekly dose across two administrations smooths serum testosterone fluctuation; bioavailability remains near-complete regardless of injection-day schedule
Pre-PCT Washout (Weeks 13–14)	Final injection administered; no new dosing	Allow approximately 14 days post-final injection before initiating PCT, permitting circulating esterified testosterone to clear sufficiently for HPTA recovery signalling
TRT / Therapeutic Use	100–200 mg per week (0.33–0.67 ml)	Conservative physiological replacement range; injectable route ensures the full stated dose contributes to systemic androgen levels without oral metabolic losses

Key takeaways

Choose injectable cypionate to achieve near-complete systemic testosterone bioavailability.
Understand that oral testosterone loses up to 98% of dosage through first-pass metabolism.
Confirm every batch with HPLC potency assay before administering any injectable compound.
Draw with a wide-gauge needle, then switch to fine gauge for injection comfort.
Store opened vials at 15–25°C and use strict aseptic technique at every puncture.

Why Injectable Testosterone Cypionate Delivers Virtually Complete Bioavailability

GenTec Testo-C 300 is defined as a high-concentration intramuscular depot preparation of Testosterone Cypionate (300 mg/ml, 10 ml vial) whose primary pharmacological advantage lies in circumventing the hepatic first-pass elimination that renders oral testosterone largely ineffective as a mass-gaining or TRT compound. When testosterone is administered orally, the gastrointestinal tract and liver metabolise the majority of the molecule before it reaches systemic circulation — a process quantified in pharmacokinetic literature as leaving only 2–12% of the oral dose bioavailable (Sundaram et al., 1995, Journal of Clinical Endocrinology & Metabolism). Intramuscular injection eliminates this barrier: the cypionate ester depot releases testosterone directly into the lymphatic and vascular supply, delivering bioavailability approaching 100% of the injected mass.

First-Pass Metabolism: The Core Distinction

First-pass metabolism governs why oral testosterone 17-alpha alkylation was historically required to survive liver transit — and why alkylated androgens carry hepatotoxicity profiles that injectable esters do not. Testosterone Cypionate reaches systemic circulation without hepatic pre-processing, meaning the liver encounters free testosterone only after it has already entered general circulation and undergone normal physiological distribution. This distinction makes injectable cypionate substantially safer for the liver compared to oral androgens across equivalent androgenic doses. Serum testosterone concentration after a 300 mg intramuscular dose of GenTec Testo-C 300 rises measurably within 24–48 hours, with peak plasma levels typically observed between day 2 and day 4 post-injection based on established cypionate pharmacokinetic modelling.

Absorption Pathway and Concentration Advantage

The 300 mg/ml concentration of Testo-C 300 delivers 50% more active compound per millilitre than standard 200 mg/ml reference preparations, reducing injection volume for equivalent doses — a clinically relevant benefit for high-frequency administration schedules. Oil-based depot absorption occurs as the esterase enzyme network in muscle tissue cleaves the cypionate ester bond, releasing free testosterone into interstitial fluid and subsequently into capillary circulation. GenTec's New Formula specification subjects each batch to HPLC quantitative potency assay and LAL (Limulus Amebocyte Lysate) endotoxin testing, confirming that the stated 300 mg/ml concentration is pharmacologically accurate and that the injectable solution is pyrogen-free before release.

Usage

Verify the vial label confirms Testosterone Cypionate 300 mg/ml and inspect the oil solution for visible particulate matter or unusual discolouration before drawing.
Warm the vial to room temperature (if stored cold) by holding it in your palm for 2–3 minutes; warmer oil flows more readily through the needle, improving draw accuracy.
Wipe the rubber septum with a 70% isopropyl alcohol swab and allow it to air-dry for 10 seconds to maintain aseptic conditions at every puncture.
Draw the calculated volume using an 18–21 gauge needle attached to a luer-lock syringe; the high-concentration 300 mg/ml oil requires adequate gauge to draw efficiently without prolonged suction.
Swap the draw needle for a sterile 23–25 gauge, 1–1.5 inch injection needle; inject slowly into the chosen intramuscular site (gluteus medius, vastus lateralis) over 30–60 seconds to minimise pressure-related discomfort.
Apply light pressure with a sterile swab post-injection; do not recap used needles — dispose of all sharps immediately in an approved sharps container and record dose, date, and injection site for monitoring continuity.

Warnings

Contraindications: Testo-C 300 must not be used by individuals with confirmed or suspected androgen-sensitive malignancies (prostate or breast carcinoma), active polycythaemia, severe untreated obstructive sleep apnoea, or known hypersensitivity to any component of the oil-based vehicle. Women who are pregnant or breastfeeding must not use this product due to established foetal virilisation risk.

Side Effects: Androgen-related side effects include acne, accelerated androgenetic alopecia in genetically predisposed individuals, and potential for oedema secondary to mineralocorticoid receptor activity. Aromatisation to oestradiol can produce gynaecomastia and water retention; an aromatase inhibitor may be warranted based on bloodwork. Polycythaemia (elevated haematocrit) is a well-documented consequence of exogenous testosterone and requires periodic haematological monitoring.

Monitoring: Serum testosterone, LH, FSH, haematocrit, haemoglobin, lipid panel (HDL/LDL), PSA (in males over 40), and liver enzymes should be assessed at baseline, at week 6, and at cycle conclusion. HPLC-verified product accuracy does not negate the need for individual bloodwork, as physiological response varies between users.

PCT: Post-cycle therapy using a selective oestrogen receptor modulator (SERM such as Nolvadex or Clomid) should commence approximately 14 days following the final Testo-C 300 injection to allow sufficient ester clearance before HPTA stimulation. PCT duration of 4–6 weeks is standard practice for cycles of 10–16 weeks duration.

Frequently asked questions

Why does injectable Testosterone Cypionate have higher bioavailability than oral testosterone?: Injectable Testosterone Cypionate bypasses first-pass hepatic metabolism entirely, delivering close to 100% of the injected dose into systemic circulation. Oral testosterone, by contrast, is degraded extensively in the gastrointestinal tract and liver before reaching the bloodstream, with published pharmacokinetic data indicating only 2–12% of the oral dose survives to produce systemic androgenic effect.
What exactly is first-pass metabolism and how does it affect testosterone compounds?: First-pass metabolism refers to the liver's pre-systemic elimination of a compound absorbed from the gut before it reaches general circulation. For testosterone, this process is so extensive that unmodified oral testosterone is pharmacologically ineffective at standard doses. It is why oral androgens require structural modification (17-alpha alkylation) to survive liver transit — modifications that simultaneously introduce hepatotoxicity risk absent from injectable ester formulations like Testo-C 300.
How quickly does Testosterone Cypionate absorb after an intramuscular injection?: After intramuscular injection of an oil-based cypionate preparation, the depot begins releasing free testosterone as tissue esterases cleave the cypionate ester bond. Measurable serum testosterone elevation occurs within 24–48 hours, with peak plasma concentrations typically reached between 48 and 96 hours post-injection. This gradual, sustained absorption profile distinguishes long-ester injectables from both oral forms and short-ester injectable preparations.
Can I draw GenTec Testo-C 300 into an insulin syringe, and what needle gauge is recommended?: Due to its oil-based carrier and 300 mg/ml concentration, Testo-C 300 is viscous and not well-suited for drawing through insulin syringe gauges. The recommended practice is to draw the dose using an 18–21 gauge needle to overcome oil resistance, then swap to a finer 23–25 gauge needle for the actual intramuscular injection to minimise injection-site discomfort and tissue trauma.
How should a GenTec Testo-C 300 vial be stored after first opening?: After the rubber septum is first punctured, the vial should be stored upright at room temperature (15–25°C), away from direct light and heat sources. Refrigeration is not required but is acceptable; however, cold oil increases viscosity and should be warmed to room temperature before drawing. The benzyl alcohol preservative system in multi-dose vials maintains sterility for the duration of use when aseptic technique is observed consistently between punctures. (2) angle_used

Manufacturer

GenTec's approach to product packaging centres on the multi-dose vial as its primary delivery format — a choice that reflects deliberate decisions around dosing flexibility, logistics efficiency, and the practical realities of extended administration schedules in injectable androgenic compounds. The 10 ml vial format selected for Testo-C 300 is stoppered with a pharmaceutical-grade rubber septum designed to maintain closure integrity through repeated punctures while the benzyl alcohol preservative system within the solution sustains sterility between uses. Labelling on each vial carries batch-specific information traceable to the manufacturing-site documentation package, enabling retrospective quality verification if any supply-chain query arises. GenTec's packaging qualification process evaluates septum reseal performance, container-closure integrity under simulated transport stress, and label adhesion durability across the temperature ranges encountered during international distribution — criteria that are particularly relevant for oil-based injectables, where container integrity directly affects both sterility and volume-measurement accuracy across the life of the vial.

Product details

Brand	GenTec
Active ingredient	testosterone cypionate
Also known as	Testosterone Cypionate, Test C, Depo-Testosteronee, Testo-C 300, GenTec Testosterone Cypionate
Strength	300 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TCYP-GEN-300-009

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Cipandrol 200mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Cipandrol 200mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Cipandrol is a pharmaceutical-grade injectable testosterone preparation built around Testosterone Cypionate at 200 mg/ml — a compound whose origins trace back to American clinical research of the 1950s, when chemists at Upjohn first attached the cypionate ester to extend testosterone's therapeutic window. Presented in individual glass ampoules (10 × 1 ml), each unit delivers a precise, single-use dose free from the cross-contamination risk inherent in repeatedly punctured multi-dose vials. Sterility and potency are verified through independent HPLC quantification and LAL endotoxin screening conducted at Balkan Pharmaceuticals' GMP-certified Chișinău facility.

€38.00

High Concentration

Cypo-Testosterone 200mg/ml 10ml Vial by Beligas Pharmaceuticals

Cypo-Testosterone by Beligas Pharmaceuticals is a single-ingredient injectable androgen — Testosterone Cypionate at 200 mg per millilitre in a 10 ml multi-dose vial — engineered specifically to slot into structured, periodised cycle frameworks. At this concentration, each 1 ml draw delivers a precise 200 mg dose, giving cycle planners clean arithmetic when calculating weekly volume across bulking, maintenance, or recomposition phases. Quality assurance is enforced at every stage: HPLC-verified potency, LAL endotoxin testing, and GMP-certified filling conditions underpin every vial released under the Beligas label.

€38.00

Testacyp-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Testacyp-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testacyp-250 is an oil-based injectable testosterone ester in which Testosterone Cypionate at 250 mg/ml is engineered around its extended pharmacokinetic profile — delivering a clinically measurable half-life of approximately 8 days that sustains androgen receptor saturation between injections. Each 1 ml single-dose ampoule provides precise, pre-measured delivery in a hermetically sealed format that eliminates multi-use contamination risk. Quality assurance at BM Pharmaceuticals is built into every production stage: HPLC potency verification, LAL endotoxin screening, and GMP-certified fill-finish operations underpin every released batch.

€38.00

Brand Quality

CypioTrex 350mg/ml 10ml Vial by Concentrex Labs

CypioTrex is a high-concentration testosterone cypionate injectable — 350 mg/ml in a 10 ml multi-dose vial — engineered specifically for athletes running structured cruise-and-blast protocols that require distinct, clearly separated androgenic phases. At 350 mg/ml, each millilitre delivers 75% more active compound than standard 200 mg/ml preparations, reducing injection volume while maintaining full dosing flexibility across both the high-output blast window and the lower-dose cruise interval. Every batch is released only after passing in-house HPLC potency verification and LAL endotoxin screening, with GMP-aligned documentation supporting each production stage.

€38.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00